In the field of pediatric medicine, mucosal vaccination has come into view
as a game changer with regard to the prevention of infectious diseases among children.
This chapter thoroughly discusses recent developments, challenges, and future
prospects of mucosal vaccination in pediatric population. It also starts by explaining the
peculiarities of mucosal immunity in children while emphasizing the significance of
aiming at these surfaces for vaccine delivery. It also looks at the varied benefits that
come with mucosal vaccines, such as their ability to provoke robust immune responses
both locally and systemically, be given without using a needle, and fight against the
infections mentioned above most effectively, which is very significant for young
children. Besides, the chapter provides an extensive overview of the current status of
mucosal vaccines in relation to pediatric infectious illnesses targeting respiratory
system infections, gastrointestinal ailments, and sexually transmitted diseases. This
chapter provides insight into the clinical relevance and potential impact of mucosal
vaccination on pediatric healthcare practice. It does this by analyzing recent
developments in mucosal vaccine research and clinical trials aimed at combating
common childhood infections such as influenza, rotavirus, pneumococcus, and human
papillomavirus (HPV). However, despite the possibility of mucosal vaccination, this
chapter also highlights a number of problems that need to be overcome in order to
exploit its advantages fully. These encompass vaccine formulation and delivery issues,
regulatory affairs, public acceptance of the technology, and healthcare infrastructure.
However, the section ends on an optimistic note by discussing future research
directions and strategies for overcoming these challenges. New methods of
immunizing, a composition containing adjuvants, substances capable of increasing
mucosal adherence, and modern means of administering a drug are some other areas
that have been investigated. Finally, the use of mucosal vaccines represents the light at the end of the tunnel in treating children’s diseases, as it offers hope for decreasing
infectious diseases and alleviating children’s suffering across the globe. We can,
therefore, use the transformative effect of mucosal vaccination and ensure the equal
distribution of life-saving vaccines for all children, ushering in a new era of pediatric
health by promoting cooperation among academia, industry, healthcare providers, and
policymakers.
Keywords: Chlamydia, Gonorrhea, Human papillomavirus, Healthcare, Sexually transmitted infections, Urinary tract infections, Urogenital vaccine.
